Category Archives: Guideline

Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen

1 Guidance 1.1 Abiraterone in combination with prednisone or prednisolone is recommended as an option for the treatment of castration‑resistant metastatic prostate cancer in adults, only if: their disease has progressed on or after one docetaxel‑containing chemotherapy regimen, and the manufacturer provides abiraterone in accordance with the commercial access arrangement as agreed with NHS England. 1.2 People […]

Ab interno canaloplasty for open-angle glaucoma

1 Recommendations 1.1 Evidence on the safety of ab interno canaloplasty for open-angle glaucoma shows no major safety concerns. Evidence on the efficacy is limited in quality and quantity, particularly in the long term. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean […]

Ab externo canaloplasty for primary open-angle glaucoma

1 Recommendations 1.1 Current evidence on the safety and efficacy of ab externo canaloplasty for primary open-angle glaucoma is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit. 1.2 Ab externo canaloplasty for primary open-angle glaucoma should only be done by clinicians with specific training […]

Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence

1 Recommendations 1.1 Abemaciclib with endocrine therapy is recommended, within its marketing authorisation, as an option for adjuvant treatment of hormone receptor-positive, HER2-negative, node‑positive early breast cancer in adults whose disease is at high risk of recurrence, defined by the following clinical and pathological features: at least 4 positive axillary lymph nodes, or 1 to 3 […]

Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer

1 Recommendations 1.1 Abemaciclib with an aromatase inhibitor is recommended, within its marketing authorisation, as an option for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer as first endocrine-based therapy in adults. Abemaciclib is recommended only if the company provides it according to the commercial arrangement. Why the committee […]